A Global Phase III Trial of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3
880
about 4.9 years
18+
73 sites in AR, AZ, CA +26
What this study is about
Researchers are testing whether rilvegostomig, in combination with platinum-based chemotherapy, is effective and safe as a first-line treatment for people whose lung cancer cells express PD-L1. The trial will last about 1785 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Carboplatin
- 2.Take Nab-paclitaxel
- 3.Take Paclitaxel
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
carboplatin, paclitaxel (Taxane chemotherapy; stabilizes microtubules), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion, injection, intravenous
Primary: Overall survival (OS), Progression-free survival (PFS)
Secondary: Duration of response (DoR), Landmark overall survival (OS) rates, Landmark progression-free survival (PFS) rates, Overall response rate (ORR), Patient-reported global health status (GHS)/quality of life (QoL), Patient-reported lung cancer symptoms of non-small cell lung cancer (NSCLC), Pharmacokinetic (PK) of rilvegostomig, Time to second progression or death (PFS2)
Oncology